Non-Hodgkin lymphoma Medical Services in China

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant cancers originating from lymphoid tissue—primarily B lymphocytes (90% of cases), but also T cells or natural killer (NK) cells. Unlike Hodgkin lymphoma, NHL lacks the characteristic Reed-Sternberg cells and encompasses over 60 distinct subtypes, broadly classified as indolent (e.g., follicular lymphoma, marginal zone lymphoma), aggressive (e.g., diffuse large B-cell lymphoma—DLBCL, the most common subtype worldwide), and highly aggressive (e.g., Burkitt lymphoma). Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), mutations in epigenetic regulators (e.g., EZH2, CREBBP), immune evasion mechanisms, and chronic antigenic stimulation. Dysregulation of B-cell receptor signaling, NF-κB activation, and impaired tumor surveillance by T cells and NK cells further drive clonal expansion and survival of malignant lymphocytes. Epidemiologically, NHL incidence rises with age, with median diagnosis at 67 years; it accounts for ~4% of all cancers globally. In China, age-standardized incidence is approximately 5.2 per 100,000 persons annually, slightly lower than in North America or Western Europe but increasing steadily—likely due to aging populations, improved diagnostics, and environmental shifts. Key risk factors include immunosuppression (e.g., HIV infection, post-transplant immunosuppressive therapy), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), chronic infections (e.g., Epstein-Barr virus, Helicobacter pylori, HTLV-1), occupational exposures (e.g., pesticides, benzene), and family history of lymphoid malignancies. Notably, obesity and certain dietary patterns are emerging modifiable risks. Quality of life (QoL) impact is profound and multifaceted: patients frequently experience debilitating fatigue, night sweats, unexplained weight loss, recurrent fevers, and painless lymphadenopathy—symptoms that disrupt daily functioning, work capacity, and psychosocial well-being. Chemotherapy-induced cytopenias increase infection risk; immunotherapies may trigger immune-related adverse events (e.g., thyroiditis, pneumonitis); and long-term survivors face elevated risks of secondary malignancies, cardiovascular toxicity, and neurocognitive decline. Psychologically, anxiety about relapse, treatment uncertainty, and financial toxicity significantly impair mental health—studies report depression prevalence up to 35% among NHL patients undergoing active therapy. Supportive care integration—including palliative oncology, nutritional counseling, physical rehabilitation, and mental health services—is now recognized as essential to preserving functional status and patient-reported outcomes throughout the disease continuum.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignancies arising from lymphoid progenitor cells—primarily B lymphocytes (90–95% of cases), less commonly T lymphocytes or natural killer (NK) cells. Unlike Hodgkin lymphoma, NHL lacks the characteristic Reed-Sternberg cell and exhibits diverse histopathological, immunophenotypic, genetic, and clinical features. The precise etiology remains incompletely understood; however, NHL is widely regarded as a multifactorial disease resulting from cumulative genetic alterations in lymphocytes, driven by dysregulated immune surveillance, chronic antigenic stimulation, and impaired DNA repair mechanisms.

Common causes and initiating events include persistent antigen-driven proliferation, particularly in the context of chronic infection or autoimmune inflammation. For instance, Helicobacter pylori infection induces gastric mucosa-associated lymphoid tissue (MALT) lymphoma via sustained B-cell activation and acquisition of t(11;18)(q21;q21), leading to API2-MALT1 fusion. Similarly, chronic hepatitis C virus (HCV) infection is associated with splenic marginal zone lymphoma and lymphoplasmacytic lymphoma, likely mediated by HCV E2 glycoprotein binding to CD81 on B cells, triggering polyclonal expansion and eventual clonal evolution. Epstein-Barr virus (EBV) contributes to NHL pathogenesis in immunocompromised hosts (e.g., post-transplant lymphoproliferative disorder, HIV-associated lymphomas) by expressing latent membrane proteins (LMP1, LMP2A) that mimic constitutive CD40 and B-cell receptor signaling, promoting survival and proliferation.

Triggers often involve acute or subacute disruptions in immune homeostasis: iatrogenic immunosuppression (e.g., calcineurin inhibitors post-solid organ transplant), untreated HIV infection with profound CD4+ T-cell depletion, or primary immunodeficiencies such as ataxia-telangiectasia or common variable immunodeficiency (CVID). These states impair cytotoxic T-cell and NK-cell surveillance, permitting outgrowth of premalignant or malignant B-cell clones.

Established risk factors include advanced age (median diagnosis age ~67 years), male sex (slight male predominance), and Caucasian ethnicity (higher incidence than Asian or Hispanic populations). Autoimmune disorders confer elevated risk—rheumatoid arthritis (RR ~2.0), Sjögren syndrome (RR ~16.0 for MALT lymphoma), systemic lupus erythematosus, and celiac disease—likely due to chronic B-cell activation and inflammatory cytokine milieu (e.g., BAFF overexpression). Prior chemotherapy or radiation therapy (especially alkylating agents and topoisomerase II inhibitors) increases risk of therapy-related myeloid neoplasms and, less consistently, NHL, possibly through induction of genomic instability.

Genetic factors play a pivotal role. Germline variants in immune-regulatory genes—including TNFAIP3 (A20), CARD11, and PRDM1—are linked to familial lymphoma predisposition. First-degree relatives of NHL patients have a 2–3-fold increased risk, suggesting polygenic inheritance. Recurrent somatic alterations define molecular subtypes: MYC, BCL2, and BCL6 translocations in high-grade B-cell lymphomas; NOTCH1/2 mutations in chronic lymphocytic leukemia/small lymphocytic lymphoma; EZH2 and CREBBP mutations in follicular lymphoma; and TP53 deletions/mutations across aggressive subtypes. Clonal hematopoiesis of indeterminate potential (CHIP) involving DNMT3A, TET2, or ASXL1 may also precede lymphoid malignancy in some elderly patients.

Environmental exposures contribute modestly but significantly. Prolonged occupational exposure to organochlorine pesticides (e.g., DDT), phenoxy herbicides (e.g., 2,4-D), benzene, and certain solvents is associated with elevated NHL incidence (ORs 1.2–2.0). Agricultural workers and pesticide applicators show consistent excess risk. Low-dose ionizing radiation (e.g., atomic bomb survivors, radiologic technologists) confers dose-dependent risk. While dietary factors lack robust causal evidence, obesity (BMI ≥30 kg/m²) is associated with a 15–20% increased risk—potentially mediated by chronic low-grade inflammation, adipokine dysregulation (leptin, adiponectin), and insulin resistance. Smoking shows inconsistent associations, though heavy, long-term use may modestly elevate risk for specific subtypes such as follicular lymphoma. Notably, no credible evidence links routine vaccinations (including influenza or HPV vaccines) or electromagnetic field exposure to NHL development. Understanding these interrelated etiologic pathways informs risk stratification, early detection strategies, and biologically rational therapeutic interventions.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant neoplasms arising from lymphoid cells—primarily B lymphocytes (90–95% of cases), less commonly T lymphocytes or natural killer (NK) cells. As a hematologic malignancy managed within hematology/oncology departments, NHL exhibits highly variable clinical behavior depending on histologic subtype (e.g., diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma), tumor grade (indolent vs. aggressive), anatomic distribution (nodal vs. extranodal), and host immune status. Symptoms often reflect tumor burden, tissue infiltration, systemic inflammation, or immune dysregulation.

Early symptoms are frequently nonspecific and insidious, leading to delayed diagnosis—particularly in indolent subtypes. Patients may report persistent fatigue, low-grade fever (<38.3°C) without identifiable infection, drenching night sweats (requiring clothing or bedding changes), and unexplained weight loss (>10% body weight over 6 months)—collectively termed 'B symptoms', which correlate with advanced disease and poorer prognosis. Early localized disease may be entirely asymptomatic and detected incidentally on imaging or routine blood work. Some patients first notice painless, firm, rubbery, non-tender lymphadenopathy—most commonly in cervical, axillary, or inguinal regions. Supraclavicular node enlargement warrants urgent evaluation due to high association with underlying malignancy. In extranodal presentations—accounting for ~30–40% of NHL cases—early symptoms depend on organ involvement: gastric NHL may cause dyspepsia, early satiety, or occult gastrointestinal bleeding; primary CNS lymphoma may present with headache, focal neurologic deficits, or cognitive changes; pulmonary involvement may manifest as dry cough or dyspnea; and primary cutaneous lymphomas may appear as persistent plaques, nodules, or ulcers resistant to topical therapy.

Typical symptoms reflect progressive lymphoid tissue expansion and systemic effects. Generalized lymphadenopathy—often symmetric and non-contiguous—is hallmark. Splenomegaly may cause left upper quadrant discomfort or early satiety; hepatomegaly is less common but may contribute to right upper quadrant pain or abnormal liver enzymes. Bone marrow infiltration (present in ~15–25% at diagnosis, higher in advanced disease) leads to cytopenias: anemia (fatigue, pallor, exertional dyspnea), thrombocytopenia (petechiae, mucosal bleeding), or neutropenia (recurrent infections). Constitutional symptoms (B symptoms) occur in ~30% of aggressive and ~15% of indolent NHL at diagnosis and signify tumor-associated cytokine release (e.g., IL-6, TNF-α). Pruritus—often generalized and refractory—is more common in T-cell lymphomas and certain B-cell subtypes. Skin involvement (in up to 25% of patients, especially in T-cell lymphomas or secondary cutaneous spread) presents as erythematous patches, papules, tumors, or ulcerations.

Accompanying symptoms arise from paraneoplastic phenomena or immune-mediated complications. Autoimmune cytopenias—including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), or Evans syndrome—are well-documented, particularly in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and splenic marginal zone lymphoma. Hypercalcemia may occur via osteoclast-activating factors (e.g., RANKL) or granulomatous vitamin D activation in some subtypes. Hypogammaglobulinemia predisposes to recurrent sinopulmonary infections. Rarely, NHL triggers paraneoplastic neurologic syndromes (e.g., cerebellar degeneration, limbic encephalitis) or dermatomyositis-like rashes. Patients with HIV-associated NHL frequently present with advanced-stage disease, CNS involvement, or EBV-driven lymphoproliferation, accompanied by opportunistic infections or wasting syndrome.

Complications stem from tumor bulk, treatment toxicity, or immunosuppression. Superior vena cava syndrome (SVCS) results from mediastinal mass compression, causing facial edema, arm swelling, and dyspnea. Spinal cord compression—due to vertebral body or epidural infiltration—presents with back pain, radicular symptoms, or rapidly progressive paralysis and constitutes an oncologic emergency. Bowel obstruction or perforation may occur with gastrointestinal lymphoma, especially in the ileocecal region. Tumor lysis syndrome (TLS) is a life-threatening metabolic emergency following initiation of cytotoxic therapy in high-burden, rapidly proliferating lymphomas (e.g., Burkitt lymphoma, DLBCL), characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and acute kidney injury. Infectious complications—including bacterial sepsis, Pneumocystis jirovecii pneumonia, or reactivated herpes zoster—are heightened due to intrinsic immune dysfunction and therapy-induced neutropenia or lymphopenia. Secondary malignancies (e.g., myelodysplastic syndrome, acute myeloid leukemia) may emerge years after alkylating agent or topoisomerase II inhibitor exposure.

Diagnosis requires integrated clinicopathologic assessment. Initial evaluation includes comprehensive history (including HIV, EBV, HCV, immunosuppressive therapy), physical exam (lymph node mapping, organomegaly, skin/ocular/neurologic assessment), and laboratory studies: complete blood count with differential, peripheral blood smear, comprehensive metabolic panel (including LDH, uric acid, calcium), serum protein electrophoresis, β2-microglobulin, lactate dehydrogenase (LDH—a prognostic biomarker), and serologies (HIV, HBV, HCV). Imaging—contrast-enhanced CT of neck/chest/abdomen/pelvis or PET/CT—is essential for staging (Ann Arbor classification) and response assessment. Definitive diagnosis mandates excisional lymph node biopsy (core needle biopsy is insufficient for architecture assessment); immunohistochemistry (CD20, CD3, CD5, CD10, BCL-2, BCL-6, MUM1, Ki-67), flow cytometry, and molecular studies (e.g., IGH/BCL2 translocation in follicular lymphoma, MYC rearrangements in double-hit lymphoma) are mandatory. Bone marrow aspiration and biopsy assess marrow involvement. CSF analysis with flow cytometry is indicated for suspected CNS lymphoma or high-risk subtypes (e.g., intravascular large B-cell lymphoma, testicular relapse).

Differential diagnosis is broad and context-dependent. Reactive lymphadenopathy (e.g., viral mononucleosis, toxoplasmosis, tuberculosis, sarcoidosis) must be excluded—often requiring microbiologic testing or granuloma characterization. Hodgkin lymphoma shares B symptoms and lymphadenopathy but differs histologically (Reed-Sternberg cells) and immunophenotypically (CD30+, CD15+, CD20−/weak). Chronic lymphocytic leukemia (CLL) overlaps clinically with SLL but is distinguished by peripheral blood lymphocytosis (>5 × 10⁹/L) and characteristic immunophenotype (CD5+, CD23+, weak surface Ig). Autoimmune disorders (e.g., systemic lupus erythematosus, Sjögren syndrome) may mimic lymphadenopathy and cytopenias. Metastatic carcinoma (e.g., from lung, breast, or melanoma) can present with isolated adenopathy and requires cytokeratin staining. Infectious causes—including HIV-related lymphoproliferative disorders, EBV+ lymphoproliferations in immunocompromised hosts, or cat-scratch disease—demand careful serologic and molecular evaluation. Finally, rare entities such as Castleman disease (especially HHV-8+ multicentric variant) or IgG4-related disease may simulate lymphoma clinically and radiographically, necessitating histologic correlation.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignancies arising from B-lymphocytes (90–95% of cases), T-lymphocytes, or natural killer (NK) cells. Management is highly individualized based on histologic subtype (e.g., diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma), disease stage (Ann Arbor classification), tumor burden, patient age, performance status, comorbidities, and molecular biomarkers (e.g., MYC/BCL2/BCL6 double-hit status, CD20 expression, TP53 mutations). Treatment in the Department of Hematology integrates risk-adapted strategies across the spectrum of disease aggressiveness.

Conservative treatment—often termed 'watchful waiting' or 'active surveillance'—is standard for asymptomatic, low-tumor-burden indolent NHL subtypes such as stage I–II follicular lymphoma with minimal nodal involvement or asymptomatic small lymphocytic lymphoma (SLL). This approach avoids premature cytotoxic exposure while preserving quality of life. Patients undergo clinical assessment every 2–3 months, including physical exam, complete blood count, lactate dehydrogenase (LDH), β2-microglobulin, and imaging (e.g., contrast-enhanced CT or PET/CT) every 6–12 months. Initiation of systemic therapy is triggered by B symptoms (fever >38°C, drenching night sweats, weight loss >10% in 6 months), progressive lymphadenopathy, cytopenias due to bone marrow infiltration, organ dysfunction (e.g., renal obstruction, pulmonary compromise), or transformation to aggressive lymphoma.

Medication-based therapies constitute the cornerstone of NHL management. First-line immunochemotherapy remains R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for fit patients with DLBCL and many other aggressive subtypes. For elderly or frail patients, dose-adjusted regimens (e.g., R-miniCHOP or R-GemOx) are employed to mitigate toxicity. In FL, frontline options include rituximab monotherapy (for very low-risk elderly patients), rituximab plus bendamustine (RB), or obinutuzumab plus chlorambucil. Novel agents have transformed relapsed/refractory (R/R) disease: Bruton tyrosine kinase inhibitors (e.g., zanubrutinib, acalabrutinib) demonstrate high efficacy in MCL and CLL/SLL; lenalidomide combined with rituximab (R²) is approved for FL and MCL; polatuzumab vedotin (an anti-CD79b antibody–drug conjugate) plus bendamustine and rituximab improves outcomes in R/R DLBCL; and chimeric antigen receptor T-cell (CAR-T) therapy (e.g., axicabtagene ciloleucel, tisagenlecleucel, and relmacabtagene autoleucel—approved in China in 2021 and 2023) has achieved durable remissions in heavily pretreated aggressive B-cell lymphomas. Bispecific antibodies (e.g., glofitamab, epcoritamab) are now integrated into later-line protocols following pivotal phase II trials. Supportive medications—including granulocyte colony-stimulating factor (G-CSF) for neutropenia prophylaxis, antiviral prophylaxis (e.g., valacyclovir) during rituximab-containing regimens, and iron supplementation or erythropoietin for anemia—are routinely prescribed to optimize tolerability.

Surgical treatment plays a limited but defined role. Surgery is not indicated for primary systemic control of NHL; however, it serves critical diagnostic and palliative functions. Excisional lymph node biopsy remains the gold standard for definitive histopathologic and immunophenotypic diagnosis—core needle biopsies are insufficient for subclassification. In localized gastrointestinal MALT lymphoma associated with Helicobacter pylori, surgical resection is rarely needed; instead, antibiotic eradication is first-line. However, surgery may be required for complications such as bowel perforation, obstruction, or hemorrhage in GI lymphoma. Rarely, localized extranodal disease (e.g., solitary orbital, cutaneous, or testicular NHL) may be managed with surgical excision followed by involved-site radiotherapy (ISRT) or systemic therapy depending on risk stratification. Splenectomy retains niche utility in splenic marginal zone lymphoma with symptomatic hypersplenism or refractory cytopenias, though rituximab-based regimens have largely superseded this approach.

Treatment advantages in China reflect rapid integration of global innovations alongside domestically developed therapeutics and infrastructure strengths. China’s National Medical Products Administration (NMPA) has accelerated approvals—over 15 novel hematology drugs received NMPA approval between 2020–2024, including multiple CAR-T products (relmacabtagene autoleucel, equecabtagene autoleucel) with manufacturing timelines under 21 days at certified centers. High-volume academic hospitals (e.g., Peking University People’s Hospital, Ruijin Hospital Shanghai Jiao Tong University School of Medicine) perform over 1,200 CAR-T infusions annually, supported by standardized apheresis networks and centralized cell-processing facilities. Cost containment is achieved via inclusion of rituximab, bendamustine, and novel oral agents in the National Reimbursement Drug List (NRDL), reducing out-of-pocket expenses by up to 70%. Furthermore, China leads globally in real-world evidence generation through the China Lymphoma Working Group (CLWG) registry, enabling rapid validation of biomarker-driven algorithms (e.g., IPI and NCCN-IPI refinements for Asian populations) and optimizing risk stratification.

Recovery advice emphasizes multidimensional rehabilitation. Patients are counseled to maintain moderate physical activity (e.g., walking ≥30 minutes/day) to counteract cancer-related fatigue and improve immune surveillance. Nutrition focuses on protein-rich, anti-inflammatory foods (e.g., legumes, fatty fish, leafy greens) while avoiding raw seafood, unpasteurized dairy, and undercooked eggs during neutropenia. Vaccination status must be reviewed: influenza and pneumococcal vaccines are recommended ≥6 months post-chemotherapy; live vaccines (e.g., varicella, MMR) are contraindicated for ≥24 months after immunosuppressive therapy. Psychosocial support—including access to certified oncology psychologists and peer-led survivorship programs—is embedded in follow-up pathways. Long-term monitoring includes CBC and LDH every 3 months for first 2 years, then every 6 months for years 3–5, with annual PET/CT only if clinically indicated (not routine surveillance). Secondary malignancy screening (e.g., colonoscopy, mammography, low-dose CT lung) follows age- and risk-appropriate guidelines. Finally, fertility preservation counseling (sperm/egg cryopreservation) is offered prior to alkylator-based regimens, especially for patients <40 years. Adherence to scheduled surveillance and prompt reporting of new symptoms (e.g., persistent fever, unexplained bruising, lymph node enlargement) remain essential for early detection of relapse or late toxicities such as secondary myeloid neoplasms or cardiac dysfunction following anthracycline exposure.